Darlene M Deptula Hicks Net Worth

The estimated Net Worth of Darlene M Deptula Hicks is at least $49.8 Thousand dollars as of 6 June 2017. Darlene Hicks owns over 4,000 units of Xenetic Biosciences Inc stock worth over $14,760 and over the last 17 years Darlene sold XBIO stock worth over $35,000.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Darlene Hicks XBIO stock SEC Form 4 insiders trading

Darlene has made over 4 trades of the Xenetic Biosciences Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently Darlene bought 4,000 units of XBIO stock worth $14,320 on 6 June 2017.

The largest trade Darlene's ever made was selling 25,000 units of Xenetic Biosciences Inc stock on 9 March 2010 worth over $35,000. On average, Darlene trades about 2,294 units every 156 days since 2007. As of 6 June 2017 Darlene still owns at least 4,000 units of Xenetic Biosciences Inc stock.

You can see the complete history of Darlene Hicks stock trades at the bottom of the page.

What's Darlene Hicks's mailing address?

Darlene's mailing address filed with the SEC is C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA, NH, 03062.

What does Xenetic Biosciences Inc do?

xenetic biosciences (nasdaq: xbio) is a clinical-stage biopharmaceutical company focused on discovery, research and development of next-generation biologic drugs and novel oncology therapeutics. xenetic's proprietary drug development platforms include polyxen™, which enables next generation biologic drugs by improving their half-life and other pharmacological properties. xenetic's lead investigational product candidates include fda orphan designated oncology therapeutic sodium cridanimod for the treatment of progesterone receptor negative endometrial cancer, and a polysialylated form of erythropoietin for the treatment of anemia in pre-dialysis patients with chronic kidney disease. xenetic is also working together with shire plc (formerly baxalta, baxter incorporated and baxter healthcare) to develop a novel series of polysialylated blood coagulation factors, including a next generation factor viii. this collaboration relies on xenetic's polyxen technology to conjugate polysialic acid

Complete history of Darlene Hicks stock trades at Icad Inc, Pieris Pharmaceuticals Inc, T2 Biosystems Inc, and Xenetic Biosciences Inc

Xenetic Biosciences Inc executives and stock owners

Xenetic Biosciences Inc executives and other stock owners filed with the SEC include:

• Jeffrey F. Eisenberg Esq.,
  CEO, Pres & Director
• James F. Parslow,
  CFO, COO & Corp. Sec.
• Dr. Curtis A. Lockshin,
  Chief Scientific Officer
• Colin Hill,
  Treasurer, Secretary, Director
• Grigory Borisenko,
  Director
• Adam Logal,
  Independent Director
• Dmitry Genkin,
  Independent Director
• James Callaway,
  Independent Director
• Roger Kornberg,
  Director
• Artur Isaev,
  Director
• Firdaus Dastoor,
  Director
• Timothy Cote,
  Director
• Curtis Lockshin,
  Chief Scientific Officer
• James Parslow,
  Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
• Jeffrey Eisenberg,
  Chief Executive Officer, Chief Operating Officer, Director
• Moshe Mizrahy,
  Director
• Darlene M Deptula Hicks,
  Director
• Alexey Andreevich Vinogradov,
  Director
• Michael Scott Maguire,
  CEO
• Edward J. Jr Benz,
  Director